about
Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA.Case Report: Treatment of systemic mastocytosis with sunitinib.White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome.Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness
P50
description
researcher
@en
name
G J Molderings
@en
type
label
G J Molderings
@en
prefLabel
G J Molderings
@en
P31
P496
0000-0002-9005-2749